Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-294 dose-ranging study in adults with moderate-to-severe atopic dermatitis
2026-526184-38-00Phase 2Authorised
- Sponsor
- Enveda Biosciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ENV-294 dose arm(s) with Placebo (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index score at Week 12. Planned start Sep 2026; status: authorised.
02
Drugs
ENV-294
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2026-526184-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526184-38-00.